MoonLake Immunotherapeutics (MLTX) Cash & Equivalents Growth (3y) (2023 - 2026)
MoonLake Immunotherapeutics (MLTX) Cash & Equivalents Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 13.29% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.63% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -16.07% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -8.88% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | MoonLake Immunotherapeutics | 1.35 Bn | 991.29 Mn | - | 81.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81.25% |
| Dec 31, 2025 | 103.82% |
| Sep 30, 2025 | 104.18% |
| Mar 31, 2025 | 2,166.12% |
| Dec 31, 2024 | 182.08% |
| Sep 30, 2024 | 614.76% |
| Jun 30, 2024 | 578.45% |
| Mar 31, 2024 | 631.74% |
| Dec 31, 2023 | 596.39% |